Improving patient convenience and eliminating dissociative side effects of ketamine for the treatment of TRD
The Ketabon program, a joint venture between HMNC Brain Health and Develco Pharma in Switzerland comprises an oral prolonged-release formulation of ketamine for Treatment-Resistant Depression (TRD).
The pharmacokinetic profile of this prolonged release (PR) formulation could significantly improve the risk profile and patient convenience, by minimizing dissociative side effects compared with the currently applied intravenous and intranasal therapies.
TRD patients with insufficient response to standard antidepressants represent 30% of all patients suffering from Major Depressive Disorder (MDD). In this group, ketamine PR has shown high response rates.
HMNC Brain Health is also advancing its investigational oral prolonged-release formulation of ketamine PR for the treatment of TRD with a clinical Phase-II study .